F. Hoffmann-La Roche Ltd: Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting

Long-term data at the European Hematology Association (EHA) 2022 congress expands understanding of the impact of Roche medicines in early-stage blood cancers with the goal of providing patients with robust

Related Keywords

Taiwan ,Japan ,United States ,Hong Kong ,China ,Austria ,Vienna ,Wien ,South Korea ,Switzerland ,America ,American ,Nathalie Meetz ,Levi Garraway ,Mabthera Rituxan ,Gazyva Gazyvaro ,Sabine Borngr ,Gerard Tobin ,Bruno Eschli ,Sileia Urech ,Venclexta Venclyxto ,Birgit Masjost ,Loren Kalm ,Karsten Kleine ,American Society Of Clinical Oncology ,Genentech ,European Commission ,European Hematology Association ,Drug Administration ,Head Of Global Product Development ,European Medicines Agency ,Roche Group ,Roche Group Media Relations ,Chief Medical Officer ,Global Product ,American Society ,Clinical Oncology ,Breakthrough Therapy Designations ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Roche Group Media ,Hoffmann ,Oche ,Nnounces ,Positive ,Data ,Rom ,Road ,Flood ,Dancer ,Portfolio ,European ,Hematology ,Association ,Nnual ,Meeting ,